Biotech IP and strategy briefing exploring how a company's recent intellectual-property development could influence its clinical and commercial planning.
Key Takeaways
- USPTO issued a Notice of Allowance for a crystalline formulation patent extending protection through 2045
- Company can seek a five-year patent term extension to extend protection to 2050
- Use this formulation in planned registrational trials for DLB psychosis